文献速递妇科生殖医学

新辅助化疗后保留生育功能手术用于2-4cm宫颈癌:新兴数据与未来展望

Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.
PubMed 文献 · Gynecol Oncol · 2021-06-12

本系统综述纳入18篇文章共249例患者,最终分析114例FIGO 2018 IB2期宫颈癌患者,均接受新辅助化疗后保留生育功能手术。64次尝试妊娠中49次(76.6%)活产,复发率6.1%,2例(1.8%)死于疾病。结论认为该策略对希望保留生育功能的2-4cm宫颈癌患者是可选方案。

要点

  • 新辅助化疗后保留生育功能手术可用于2-4cm宫颈癌且不牺牲肿瘤或产科结局。
  • 最终分析114例IB2期患者,64次尝试妊娠中49次(76.6%)活产。
  • 复发率6.1%,2例(1.8%)死于疾病,需国际II期试验进一步验证。

核心结论

  • 对新辅助化疗后保留生育功能手术的2-4cm宫颈癌患者,该策略不牺牲肿瘤或产科结局,可作为希望保留生育功能患者的选择。

研究设计与样本

  • 系统文献综述,检索PubMed、Google Scholar、Cochrane Reviews和UpToDate(2000年1月至2021年2月)。
  • 共识别18篇文章包括249例患者,最终分析114例符合纳入标准。
  • 纳入患者均为FIGO 2018 IB2期宫颈癌,接受新辅助化疗及后续保留生育功能手术。

主要发现

  • 手术方式包括阴道根治性子宫颈切除术46例(40.4%)、冷刀锥切26例(22.8%)、腹式根治性子宫颈切除术14例(12.3%)、腹腔镜根治性子宫颈切除术13例(11.4%)、简单阴道子宫颈切除术8例(7%)、锥形激光7例(6.1%)。
  • 最常见化疗方案为以顺铂为基础的铂类治疗。
  • 所有研究报告的随访时间范围为1至225个月。
  • 64次尝试妊娠中,49次(76.6%)为活产,包括6例早产(9.4%)。
  • 复发率为6.1%,2例患者(1.8%)死于疾病。

临床怎么用

  • 对于肿瘤大小2-4cm、希望保留生育功能的宫颈癌患者,可考虑新辅助化疗后保留生育功能手术。
  • 需向患者说明该策略的肿瘤学结局(复发率6.1%、疾病死亡1.8%)和产科结局(活产率76.6%、早产率9.4%)。
  • 尚需正在进行的国际II期临床试验进一步证实这些发现。

局限性

  • 本文为系统综述,纳入研究多为回顾性,证据级别有限。
  • 随访时间范围宽(1至225个月),各研究间异质性可能较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approach to the management of early stage cervical cancers with tumor size >2 cm in women who desire fertility preservation has been fraught with controversy. Fertility sparing surgery for FIGO 2018 stage IB cancers has been validated most for tumors ≤2 cm. In this review, our objective was to evaluate the oncologic and obstetric outcomes for women that underwent neoadjuvant chemotherapy (NACT) before fertility sparing surgery for tumors 2-4 cm. METHODS: We performed a systematic literature review and searched PubMed, Google Scholar, Cochrane Reviews and UpToDate (from January 2000 to February 2021) using the terms: cervical cancer, fertility preservation, trachelectomy, radical trachelectomy, neoadjuvant chemotherapy, cervical cancer treatment, stage IB1 or IB2 cervical cancer, and cervical cancer size 2-4 cm. We included manuscripts with information on patients with tumor sizes 2-4 cm, lymph node status, follow-up, obstetric and oncologic outcome. We excluded review articles or articles without all pertinent patient information. RESULTS: Eighteen articles were identified including 249 patients. For final analysis, 114 met inclusion criteria. All included patients had FIGO 2018 stage IB2 cervical cancer, underwent neoadjuvant chemotherapy and subsequent fertility sparing surgery. Vaginal radical trachelectomy, cold knife conization, abdominal radical trachelectomy, laparoscopic radical trachelectomy, simple vaginal trachelectomy, and cone laser were performed in 46 (40.4%), 26 (22.8%), 14 (12.3%), 13 (11.4%), 8 (7%), and 7 (6.1%) women, respectively. The most common regimen of chemotherapy was platinum-based therapy with cisplatin. The follow-up time reported in all studies ranged from 1 to 225 months. Of 64 attempted pregnancies, there were 49 (76.6%) viable deliveries which included 6 preterm births (9.4%). The recurrence rate was 6.1% and two patients (1.8%) died of disease. CONCLUSION: Fertility sparing surgery following NACT is an option for women with cervical cancers that are 2-4 cm that wish to preserve fertility without sacrificing oncologic or obstetric outcomes. Confirmation of these findings are anticipated from an ongoing international phase II clinical trial [1].

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gwacham NI, McKenzie ND, Fitzgerald ER, et al. Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives. Gynecol Oncol. 2021. PMID: 34130862. doi:10.1016/j.ygyno.2021.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。